Species difference in enantioselectivity for the oxidation of propranolol by cytochrome P450 2D enzymes

Chemico-Biological Interactions

Volumn 127, Issue 1, 2000, Pages 73-90

  Narimatsu, Shizuo ^a   Kobayashi, Naoko ^b   Masubuchi, Yasuhiro ^b   Horie, Toshiharu ^b   Kakegawa, Tomohito ^b   Kobayashi, Hiroshi ^b   Hardwick, James P ^c   Gonzalez, Frank J ^d   Shimada, Noriaki ^e   Ohmori, Shigeru ^f   Kitada, Mitsukazu ^f   Asaoka, Kazuo ^g   Kataoka, Hiroyuki ^a   Yamamoto, Shigeo ^a   Satoh, Testuo ^h  

^a OKAYAMA UNIVERSITY   (Japan)

^b CHIBA UNIVERSITY   (Japan)

^c Northwestern Ohio Universities   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

^e Kyoto University   (Japan)

^f CHIBA UNIVERSITY HOSPITAL   (Japan)

^g KYOTO UNIVERSITY   (Japan)

^h Biomedical Research Institute   (Japan)

Author keywords

CYP2D6; Enantioselectivity; Heterologous expression system; Human liver microsomes; Monkey liver microsomes; Propranolol

Indexed keywords

CYTOCHROME P450; PROPRANOLOL;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG METABOLISM; ENANTIOMER; FEMALE; HUMAN; HUMAN TISSUE; LIVER MICROSOME METABOLISM; MALE; NONHUMAN; OXIDATION; SPECIES DIFFERENCE; STEREOCHEMISTRY; STEREOSPECIFICITY;

ANIMALS; BACULOVIRIDAE; CYTOCHROME P-450 CYP2D6; HUMANS; HYDROXYLATION; KINETICS; MACACA; MICROSOMES, LIVER; OXIDATION-REDUCTION; PROPRANOLOL; RECOMBINANT PROTEINS; SPECIES SPECIFICITY; SPODOPTERA; STEREOISOMERISM; SUBSTRATE SPECIFICITY; TRANSFECTION;

ANIMALIA; INSECTA; MACACA FUSCATA;

EID: 0034659108     PISSN: 00092797     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-2797(00)00174-5     Document Type: Article

References (44)

1. Kroemer H.K., Eichelbaum M. 'It's the gene, stupid': molecular bases and clinical consequences of genetic cytochrome P450 2D6 polymorphism. Life Sci. 56:1995;2285-2298.
2. Gonzalez F.J. The CYP2D subfamily. Ioannides C. Cytochromes P450: Metabolic and Toxicological Aspects. 1996;183-210 CRC Press, Boca Raton, FL.
3. Meyer U.A., Zanger U.M. Molecular mechanisms of genetic polymorphisms of drug metabolism. Ann. Rev. Pharmacol. Toxicol. 37:1997;268-296.
4. Nelson D., Koymans L., Kamataki T. et al. P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics. 6:1996;1-42.
5. Igarashi T., Sakuma T., Isogai M., Nagata R., Kamataki T. Momoset liver cytochrome P450s: study for expression and molecular cloning of their cDNAs. Arch. Biochem. Biophys. 339:1997;85-91.
6. Souhaili-el Amri H., Batt A.M., Siest G. Comparison of cytochrome P-450 content and activities in liver microsomes of seven animal species, including man. Xenobiotica. 16:1986;351-358.
7. Stevens J.C., Shipley L.A., Cashman J.R., Vandenbranden M., Wrighton S.A. Comparison of human and rhesus monkey in vitro phase I and phase II hepatic drug metabolism activities. Drug Metab. Dispos. 21:1993;753-760.
8. Bullock P., Pearce R., Draper A. et al. Induction of liver microsomal cytochrome P450 in cynomolgus monkeys. Drug Metab. Dispos. 23:1995;736-748.
9. Weaver R., Thompson S., Smith G., Dickins M., Elcombe C., Mayer R., Burke M. A comparative study of constitutive and induced alkoxyresorufin O-dealkylation and individual cytochrome P450 forms in cynomolgus monkey (Macacca fascicularis), human, mouse, rat and hamster microsomes. Biochem. Pharmacol. 47:1994;763-773.
10. Sharer J.E., Shipley L.A., Vandenbranden M.R., Binkley S.N., Wrighton S.A. Comparisons of phase I and phase II in vitro hepatic enzyme activities of human, dog, rhesus monkey, and cynomolgus monkey. Drug Metab. Dispos. 23:1995;1231-1241.
11. Prueksaritanont T., Gorham L.M., Hochman J.H., Tran L.O., Vyas K.P. Comparative studies of drug-metabolizing enzymes in dog, monkey, and human samll intestines, and in Caco-2 cells. Drug Metab. Dispos. 24:1996;634-642.
12. Masubuchi Y., Iwasa T., Hosokawa S. et al. Selective deficiency of debrisoquine 4-hydroxylase activity in mouse liver microsomes. J. Pharmacol. Exp. Ther. 282:1997;1435-1441.
13. Suzuki T., Narimatsu S., Fujita S., Masubuchi Y., Umeda S. Impairment of bunitrolol 4-hydroxylase activity in liver microsomes of Dark Agouti rats. Biochem. Pharmacol. 42:1991;2241-2244.
14. Suzuki T., Narimatsu S., Fujita S., Masubuchi Y., Umeda S., Imaoka S., Funae Y. Purification and characterization of a cytochrome P-450 isozyme catalyzing bunitrolol 4-hydroxylation in liver microsomes of male rats. Drug Metab. Dispos. 20:1992;367-373.
15. Narimatsu S., Gotoh M., Masubuchi Y. et al. Stereoselectivity in bunitrolol 4-hydroxylation in liver microsomes from marmosets and Japanese monkeys. Biol. Pharm. Bull. 19:1996;1429-1433.
16. Narimatsu S., Kariya S., Isozaki S. et al. Involvement of CYP2D6 in oxidative metabolism of cinnarizine and flunarizine in human liver microsomes. Biochem. Biophys. Res. Commun. 193:1993;1262-1268.
17. Narimatsu S., Huang Y., Mizukami T., Masubuchi Y., Suzuki T. Development of a high-performance liquid chromatographic method for the analysis of enantiomer/enantiomer interaction in oxidative metabolism of bunitrolol in rat liver microsomes. Anal. Biochem. 222:1994;256-261.
18. Masubuchi Y., Hosokawa S., Horie T., Ohmori S., Kitada M., Suzuki T., Narimatsu S. Cytochrome P-450 isozymes involved in propranolol metabolism in human liver microsomes: the role of CYP-2D6 as ring-hydroxylase and CYP1A2 as N-desisopropyrase. Drug Metab. Dispos. 22:1994;909-915.
19. Ono S., Tsutsui M., Gonzalez F.J. et al. Oxidative metabolism of bunitrolol by complementary DNA-expressed human cytochrome P450 isoforms in human hepatoma hepatoma cell line (Hep G2) using recombinant vaccinia virus. Pharmacogenetics. 5:1995;97-102.
20. S. Narimatsu, M. Kitada, Molecular mechanism in the stereoselective metabolism of optically active drugs: focusing on the enantioselective metabolism of bunitrolol by CYP2D enzymes, Rec. Adv. Clin. Pharmacol. 18 (1997) 29-45 (Japanese).
21. Jacqz-Aigrain E., Gueguen M., Zanger U.M., Robieux I., Alvalez F. Cytochrome P450IID subfamily in non-human primates: catalytical and immunological characterization. Biochem. Pharmacol. 41:1991;1657-1663.
22. Otton S.V., Tyndale R.F., Wu D., Inaba T., Kalow W., Sellers E.M. Catalytic and immunological similarities between monkey and human liver cytochrome P-450db1 (human cytochrome P-450 2D6). Drug Metab. Dispos. 20:1992;1-5.
23. Sharer J.E., Shipley L.A., Vandenbranden M.R., Binkley S.N., Wrighton S.A. Comparisons of phase I and phase II in vitro hepatic enzyme activities of human, dog, rhesus monkey, and cunomolgus monkey. Drug Metab. Dispos. 23:1995;1231-1241.
24. Wu D., Otton S.V., Morrow P., Inaba T., Kalow W., Sellers E.M. Human hepatic cytochrome P450 2D6-like activity in nonhuman primates: catalytic characterization in vitro. J. Pharmacol. Exp. Ther. 266:1993;715-719.
25. Prueksaritanont T., Dwyer L.M., Cribb A.E. Bufuralol 1′-hydroxylation activity in human and rhesus monkey intestine and liver. Biochem. Pharmacol. 50:1995;1521-1529.
26. Raghuram T.C., Koshakuji R.P., Wilkinson G.R., Wood A.J.J. Polymorphic ability to metabolize propranolol alters 4-hydroxypropranolol levels but not beta blockade. Clin. Pharmacol. Ther. 36:1984;51-56.
27. Oatis J.E., Russel M.P., Knapp D.R., Walle T. Ring-hydroxylated propranolol: synthesis and beta-receptor antagonism and vasodilator activities of seven isomers. J. Med. Chem. 24:1981;309-314.
28. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193:1951;265-275.
29. Omura T., Sato R. The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. J. Biol. Chem. 239:1964;2370-2378.
30. Gonzalez F.J., Skoda R.C., Kimura S. et al. Characterization of the common genetic defect in humans deficient in debrisoquine metabolism. Nature. 331:1988;442-446.
31. Buters J.T.M., Korzekwa K.R., Kunze K.L., Omata Y., Hardwick J.P., Gonzalez F.J. cDNA-directed expression of human cytochrome P450 CYP1A1 using baculovirus. Drug Metab. Dispos. 22:1994;688-692.
32. Chen L., Buters J.T.M., Hardwick J.P., Tamura S., Penman B.W., Gonzalez F.J., Crespi C.L. Expression of cytochrome P4502A6 and human NADPH-P450 oxidoreductase in the baculovirus system. Drug Metab. Dispos. 25:1997;399-405.
33. Masubuchi Y., Kagimoto N., Narimatsu S., Fujita S., Suzuki T. Regioselective contribution of the cytochrome P-450 2D subfamily to propranolol metabolism in rat liver microsomes. Drug Metab. Dispos. 21:1993;1012-1016.
34. Yamaoka K., Tanigawara Y., Nakagawa T., Uno T. A pharmacokinetic analysis program (MULTI) for microcomputer. J. Pharmacobio. Dyn. 4:1981;879-885.
35. Narimatsu1 S., Kato R., Horie T. et al. The enantioselectivity of bunitrolol 4-hydroxylation is reversed by the change of an amino acid residue from valine to methionine at position 374 of cytochrome P450-2D6. Chirality. 11:1999;1-9.
36. Marathe P.H., Shen D.D., Nelson W.L. Metabolic kinetics of pseudoracemic propranolol in human liver microsomes: enantioselectivity and quinidine inhibition. Drug Metab. Dispos. 22:1994;237-247.
37. Kimura S., Umeno M., Skoda R.C., Meyer U.A., Gonzalez F.J. The human debrisoquine 4-hydroxylase (CYP2D) locus: sequence and identification of the polymorphic CYP2D6 gene, a related gene, and pseudogene. Am. J. Human Genet. 45:1989;889-904.
38. Ellis S.W., Roland K., Ackland M.J. et al. Influence of amino acid residue 374 of cytochrome P-450 2D6 (CYP2D6) on the regio- and enantio-selective metabolism of metoprolol. Biochem. J. 316:1996;647-654.
39. Crespi C.L., Steimel D.T., Penman B.W. et al. Comparison of substrate metabolism by wild type CYP2D6 protein and a variant containing methionine, not valine, at position 374. Pharmacogenetics. 5:1995;234-243.
40. Koymans L., Vermeulen N.P., van Acker S.A. et al. A predictive model for substrates of cytochrome P450-debrisoquine (2D6). Chem. Res. Toxicol. 5:1992;211-221.
41. Lewis D.F., Eddershaw P.J., Goldfarb P.S., Tarbit M.H. Molecular modelling of cytochrome P4502D6 (CYP2D6) based on an alignment with CYP102: structural studies on specific CYP2D6 substrate metabolism. Xenobiotica. 27:1997;319-339.
42. Fujita S., Umeda S., Funae Y. et al. Regio- and stereoselective propranolol metabolism by 15 forms of purified cytochromes P-450 from rat liver. J. Pharmacol. Exp. Ther. 264:1993;226-233.
43. Shou M., Grogan J., Mancewicz J.A., Krausz K.W., Gonzalez F.J., Gelboin H.V., Korzekwa K.R. Activation of CYP3A4: evidence for the simultaneous binding of two substrates in a cytochrome P450 active site. Biochemistry. 33:1994;6450-6455.
44. Ueng Y.-F., Kuwabara T., Chun Y.-J., Guengerich F.P. Cooperativity in oxidations catalyzed by cytochrome P450 3A4. Biochemistry. 36:1997;370-381.